BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1636 related articles for article (PubMed ID: 17126425)

  • 1. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
    Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
    Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
    Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
    Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
    Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.
    Abrams SL; Steelman LS; Shelton JG; Wong EW; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
    Cell Cycle; 2010 May; 9(9):1781-91. PubMed ID: 20436278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.
    Chang F; Steelman LS; Lee JT; Shelton JG; Navolanic PM; Blalock WL; Franklin RA; McCubrey JA
    Leukemia; 2003 Jul; 17(7):1263-93. PubMed ID: 12835716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of beta3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway.
    Woods D; Cherwinski H; Venetsanakos E; Bhat A; Gysin S; Humbert M; Bray PF; Saylor VL; McMahon M
    Mol Cell Biol; 2001 May; 21(9):3192-205. PubMed ID: 11287623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
    Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
    Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.
    Steelman LS; Abrams SL; Shelton JG; Chappell WH; Bäsecke J; Stivala F; Donia M; Nicoletti F; Libra M; Martelli AM; McCubrey JA
    Cell Cycle; 2010 Apr; 9(8):1629-38. PubMed ID: 20372086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).
    Chang F; Steelman LS; Shelton JG; Lee JT; Navolanic PM; Blalock WL; Franklin R; McCubrey JA
    Int J Oncol; 2003 Mar; 22(3):469-80. PubMed ID: 12579299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion.
    Clark SS; Zhong L; Filiault D; Perman S; Ren Z; Gould M; Yang X
    Clin Cancer Res; 2003 Oct; 9(12):4494-504. PubMed ID: 14555523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade.
    Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA
    Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells.
    Shelton JG; Steelman LS; Lee JT; Knapp SL; Blalock WL; Moye PW; Franklin RA; Pohnert SC; Mirza AM; McMahon M; McCubrey JA
    Oncogene; 2003 Apr; 22(16):2478-92. PubMed ID: 12717425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human alphaA- and alphaB-crystallins prevent UVA-induced apoptosis through regulation of PKCalpha, RAF/MEK/ERK and AKT signaling pathways.
    Liu JP; Schlosser R; Ma WY; Dong Z; Feng H; Liu L; Huang XQ; Liu Y; Li DW
    Exp Eye Res; 2004 Sep; 79(3):393-403. PubMed ID: 15336502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
    Shelton JG; Moye PW; Steelman LS; Blalock WL; Lee JT; Franklin RA; McMahon M; McCubrey JA
    Leukemia; 2003 Sep; 17(9):1765-82. PubMed ID: 12970777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines.
    Chappell WH; Candido S; Abrams SL; Akula SM; Steelman LS; Martelli AM; Ratti S; Cocco L; Cervello M; Montalto G; Nicoletti F; Libra M; McCubrey JA
    Aging (Albany NY); 2020 Jun; 12(11):10194-10210. PubMed ID: 32492656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
    Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
    Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
    McCubrey JA; Abrams SL; Ligresti G; Misaghian N; Wong EW; Steelman LS; Bäsecke J; Troppmair J; Libra M; Nicoletti F; Molton S; McMahon M; Evangelisti C; Martelli AM
    Leukemia; 2008 Nov; 22(11):2080-90. PubMed ID: 18685611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 82.